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1)  Part of the Ph. D. thesis of B.I., University of Zürich, 2005. 
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The preparation of the title compounds was achieved via the ‘azirine/oxazolone method’ 
starting from the corresponding γ-hydroxy acids. Upon subjecting  the γ-hydroxy-N-[1-
(dimethylcarbamoyl)ethyl]butanamides 4 to the ‘Direct Amide Cyclization’ (DAC) 
conditions, chlorinated acids 11 or imino lactones 12 were obtained as the sole products 
instead of the expected cyclodepsipeptides A or their cyclodimers (Scheme 4). Variation 
of the substituents in 4 did not affect the outcome of the reaction and a mechanism for the 
formation of both products from the intermediate oxazolone 13 has been proposed. Under 
the acidic conditions of the DAC, the imino lactones are formed as their HCl salts 12, 
which, in polar solvents or on silicagel, react further to give the chlorinated acids 11. 
Stabilization of the imino lactones was achieved by increasing the substitution in the five 
membered ring and their structure, in the form of the hydrochlorides, was proven 
independently by X-ray crystallography (Fig. 4). A derivative 15 of the imino lactone 
12a was prepared by the reaction with the 2H-azirin-3-amine 10a; its structure was also 
established by an X-ray crystal-structure determination (Fig. 3). Furthermore, the 
structures of the ω-chloro acids 11a and 11b were determined by X-ray crystallography 
(Fig. 2). 
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1. Introduction 
 
Cyclic depsipeptides, i.e. heterodetic cyclopeptides which contain ester (depside) bonds 
as part of their backbone, have been found in many natural products, and show a wide 
spectrum of biological activity [1]. They are therefore sought after as promising lead 
compounds for drug design and discovery. Nature is a rich source of fascinating 
cyclodepsipeptides, and although the significance of incorporating a depside bond is still 
not clear, it appears to be essential for biological activity, since all-amide analogues are 
often inactive [2]. The depside bond is recognized as being more difficult to incorporate 
into the backbone than the amide bond, although macrolactonizations have been studied 
extensively [2-6], and is therefore usually pre-formed in the linear precursor prior to the 
cyclization via amide bond formation to give cyclic depsipeptides. 
The most-well-known structures in this class of natural products belong to the ion-
selective antibiotics, such as valinomycin [7], the closely related enniatin family [8], the 
actinomycins [9], and others. The reduction in the conformational freedom brought about 
by cyclization often results in higher receptor binding affinity. Frequently in these cyclic 
compounds, extra conformational restrictions are also built in, such as D-amino acids, N-
alkylated-amino acids or α,α-disubstituted amino acids.  
A very efficient method for the incorporation of the latter into depsipeptide rings, the so 
called ‘direct amide cyclization’ (DAC), has been developed in our research group in 
recent years. It has been used successfully for the synthesis of 6-, 9-, 12- and 15-
membered cyclodepsipeptides from α-hydroxy acids [10-12], as well as larger ring 
systems from α- and β-hydroxy acids [13-15]. Therefore, we were interested to 
investigate reactions of dipeptides, containing β-, γ- and δ-hydroxy acids and an α-amino 
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acid with the aim of synthesizing 7- to 9-membered analogues. As we reported earlier, 
the cyclization of β-hydroxy acid amides 1, the linear precursors of the desired 7-
membered rings, yielded only cyclodimers 3 by the dimerization  process [16][17] 
(Scheme 1, Table 1). 
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Monosubstitution at C(α) of the amino acid moiety (R3=H) did not prevent twinning, 
although the cyclization was carried out under different conditions [17]2). If, however, 
the hydroxy acid moiety in 1 was monosubstituted at C(α), no cyclic depsipeptides were 
obtained, although the formation of the intermediate 1,3-oxazol-5(4H)-one 2 has been 
monitored by IR spectroscopy. Instead, water elimination occurred, to give derivatives of 
α,β-unsaturated acid amides. 
In the present paper, we describe the results of reactions of the higher homologues of 1 
containing γ-hydroxy acids, which were carried out with the aim of obtaining either 8- or 
16-membered cyclodepsipeptides. 
 
2. Results and Discussion 
 
                                                  
2) The DAC conditions were not applicable in this case because of the sluggish formation 
of the 1,3-oxazol-5(4H)-one intermediate (cf. [18]).  
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The linear amides 4 were synthesized in five steps from the γ,δ-unsaturated aldehydes 5 
(Scheme 2). Reduction gave the pentenols 6, which were acetylated to give 73). The 
introduction of the carboxyl group was achieved by oxidative cleavage of the C=C bond 
of 7, either with Ru(IV)oxide/NaIO4 [19] or with oxone/acetone [20], although 
purification proved to be easier in the first case, thus leading to 8 in higher yields. The 
protection of the hydroxy group prevents the formation of the lactone under these 
oxidation conditions [21]. The coupling of 8 with the respective amino acid to give 9 was 
performed by the reaction with 2,2,N,N-tetramethyl- or 2,2,N-trimethyl-N-phenyl-2H-
azirine-3-amine (10a, 10b) and N,N-dimethyl-1-azaspiro[2.4]hept-1-en-2-amine (10c), 
respectively, at room temperature (‘azirine/oxazolone method’ [22][23]). Deprotection of 
the hydroxy group by treatment with LiOH in THF/H2O led to the linear precursors 4. 
                                                  
3) The need for protection of the hydroxy group arises from the fact that attempts to 
obtain the desired γ-hydroxy acids from the corresponding easily available lactones (e.g. 
4,4-dimethyltetrahydropyran-2-one) by alkaline hydrolysis failed. Upon acidification of 
the sodium salt, spontaneous lactonization occurred and only the starting lactone could be 
isolated. 
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 Table 1. Synthesized γ-Hydroxyamides 4 and Chlorinated Acids 11 
 4a/11a 4b/11b 4c/11c 4d/11a 4e/11d 4f/11e 
R1 Me H Me Me H Me 
R2 Me H Me Me Ph Ph 
R3 Me Me Me Me Me 
R4 Me Me 
CH2 CH2
CH2CH2
 
Me Me Me 
R5 a) Me Me Me Ph Ph Ph 
 
       a) R5 only in 4. 
 
Unexpectedly, the reactions of  4a-c (Table 1) under the conditions of the ‘direct amide 
cyclization’ yielded neither the 8-membered nor the 16-membered cyclodepsipeptides. 
Instead, after chromatographic workup, the chlorinated acids 11a-c were isolated as the 
sole products (Scheme 3). If the N-methyl-N-phenylamide 4d was used instead of the 
N,N-dimethylamides 4a-c, the formed product could be isolated after evaporation of the 
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solvent and washing of the residue with CH2Cl2. The isolated product was identified as 
the imino lactone hydrochloride 12a (Scheme 3). 
Scheme 3 
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At first it seems that R5 is determining the product of the reaction. Indeed, it has been 
shown that in some DAC reactions N,N-dimethyl- and N-methyl-N-phenyl amides behave 
quite differently [15]. Therefore, the cyclization of 4e and 4f was attempted under DAC 
conditions. Surprisingly, in both cases the product was not the imino lactone of type 12, 
but the chlorinated acid of type 11. Therefore, the presence of the PhN residue is not the 
reason for the different behavior of 4d under DAC conditions. 
The explanation lies in the purification process. Since N-methylaniline hydrochloride is 
soluble in CH2Cl2 [16][17] and the products of the reaction are not, the crude residue in 
the case of 4d was just washed with CH2Cl2, and thus the imino lactone was isolated as 
its hydrochloride 12a in pure form. On the other hand, Me2NH.HCl is insoluble in 
CH2Cl2, so that chromatographic workup was necessary in the case of 4a-c, which led to 
the formation of the corresponding chloro acids 11.  In the case of 4e,f, due to the 
presence of the Ph substituent in the hydroxy acid moiety, the product of the reaction was 
soluble in CH2Cl2 and no precipitate was formed. For this reason, chromatographic 
purification was required which yielded chlorinated acids 11 as the sole product (Scheme 
3).  
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It is worth mentioning, that the 1H-NMR spectrum of 12a in (D6)DMSO changes with 
time. After just half an hour at room temperature, the appearance of signals at 1.00, 1.31, 
2.09, 3.59 and 8.05 ppm was observed, which grew stronger with time, while the signals 
at 1.15, 1.56, 3.13 and 4.56 ppm diminish (Fig. 1). 
 
Fig. 1. Dynamic 1H-NMR spectrum of 12a in (D6)DMSO: a) Spectrum of 12a, b) 
Spectrum of 11a 
 
The new signals were sharp and well defined, indicating the formation of a single 
compound, rather than decomposition. After ca. 12 h at room temperature, the ratio of 
both compounds was roughly 1:1, while after 3 d only traces of the starting compound 
12a could be observed. The spectrum of the newly formed substance coincides with the 
spectrum of 11a. The same process was also observable in the 13C NMR spectrum, the 
isomerization proceeding in a variety of polar solvents such as DMF and acetone. In the 
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latter, the ratio between 12a and 11a reached 1:1 in about a week and then remained 
constant. Flash chromatography of a mixture of 11a and 12a allowed the isolation of 
analytical amounts of 12a. Finally, the instability of 12a in solution was proven in a 
control experiment in which a mixture of 12a and 11a in CH2Cl2 containing 10% of 
MeOH was stirred at room temperature. After 14 h, only the chlorinated acid 11a was 
isolated. Apparently, under the DAC reaction conditions, the initially formed product is 
the imino lactone hydrochloride 12a, which, in polar solvents, undergoes an 
isomerization to give 11a (Scheme 4). 
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A reaction mechanism for the formation of 11a and 12a is shown in Scheme 4. Treatment 
of 4d with HCl gas leads to the corresponding 1,3-oxazol-5(4H)-one 13. When no 
external nucleophiles are present, the OH group acts as a nucleophile and attacks one of 
the two electrophilic centres in the ring. If the attack occurs at the C=O group (pathway 
a), the 8-membered cyclodepsipeptide A would be formed. On the other hand, the OH 
attack at the C=N group (pathway b), would lead to the opening of the oxazolone ring 
yielding the imino lactone hydrochloride 12a. The latter can be isolated if no 
chromatographic workup is necessary. In a polar solvent, the chloride ion apparently 
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attacks the methylene group adjacent to the O-atom, which leads to the open chain ω-
chloro acid 11a4). 
 Due to its instability in solution, no crystals of 12a suitable for an X-ray crystal structure 
determination could be obtained, but the structures of the chlorinated acids 11a  and 11b 
were confirmed by X-ray crystallography (Fig. 2)5). 
                                                  
4) We expect that in the presence of a better nucleophile a competition with the attack of 
Cl- should be possible, which would lead to a mixture of products, but all reactions in the 
presence of  CsI, Bu4NI and PhSNa, respectively, led to the formation of 11 exclusively.  
5) The structure of 11c has also been proven by an X-ray crystal-structure determination. 
The quality of the crystals and, subsequently, the results of the structure determination 
were poor, although unambiguous.  The results are not reported here, but have been 
deposited at the CCDC (see footnote 6). 
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a) 
b)   
 
Fig. 2. ORTEP Plots [24] of the molecular structures of  a) 11a  and b) one of the 
disordered conformations of one of the two symmetry-independent molecules of 11b  
(arbitrary numbering of the atoms; 50% probability ellipsoids) 
 
The OH group in 11a forms an intermolecular H-bond with the amide O-atom of a 
neighboring molecule, thereby linking the molecules into extended chains which run 
parallel to the [0 1 0] direction and can be described by a graph set motif [25] of C(7).  
The amide group forms an intermolecular H-bond with the carboxylate carbonyl O-atom 
of a different neighboring molecule, thus also linking the molecules into extended chains.  
These chains run parallel to the [1 0 0] direction and can be described by a graph set 
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motif of C(5). The combination of both interactions generates a two-dimensional 
network, which lies parallel to the (0 0 1) plane. 
In the case of 11b, there are two symmetry-independent molecules in the asymmetric 
unit.  The most significant difference between the independent molecules is in the 
orientation of the Cl-atom. Furthermore, each of the two symmetry-independent 
molecules is disordered over the Cl-(CH2)3- section of the molecule. Two positions were 
defined for these atoms in each molecule, except for the Cl-substituted C-atom, which is 
common to both conformations. The major conformation is present in approximately 
65% and 80% of molecules A and B, respectively. Except for the orientations of the Cl-
atoms, the major conformation of molecule A is almost identical to that of the minor 
conformation of molecule B and vice-versa. The OH group of each molecule in 11b 
forms an intermolecular hydrogen bond with the amide O-atom of an adjacent molecule 
of the same type.  These interactions link the molecules into infinite extended chains 
composed entirely of molecules of type A or entirely of type B.  These chains run in the 
[1 0 1] direction and can be described by a graph set motif of C(7).  The amide group of 
each molecule forms an intermolecular H-bond with the carbonyl O-atom of the carboxyl 
group of an adjacent symmetry-independent molecule.  These interactions link the 
molecules into extended ···A···B···A···B··· chains which run in the [0 0 1] direction and 
can be described by a binary graph set motif of C22(10). The combination of all H-
bonding interactions links the molecules into extended two-dimensional networks which 
lie parallel to the (0 1 0) plane. 
In order to isolate the crucial intermediate 12a, extraction with aq. Na2CO3 solution [26] 
and deprotection by treatment with polyvinylpyridine were attempted, but neither 
procedure gave satisfying results. Although esterification of 12a with CH2N2 yielded the 
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corresponding crude methyl ester hydrochloride 14a  (Scheme 5), the product was also 
not stable in polar solvents and isomerized partially to the corresponding chloro ester. 
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Finally, the reaction of 12a with 2H-azirin-3-amine 10b yielded the diamide 15, which 
was stable in solution and whose structure was confirmed by X-ray crystallography (Fig. 
3). This is the first direct proof of the tetrahydrofuran-2-imine structure. 
 
 
Fig. 3. ORTEP Plot [24] of the molecular structure of 15 (arbitrary numbering of the 
atoms; 50% probability ellipsoids) 
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The central amide group (N(4)H) of 15 has a weak intramolecular H-bonding interaction 
with the imine N-atom (N(7)), which results in a five-membered loop that can be 
described by a graph set motif  [25] of S(5). 
 
When the hydroxy-protected amide 9d was subjected to the DAC conditions, the 
corresponding protected 1,3-oxazol-5(4H)-one 16a (Scheme 6) was isolated in good 
yield, which indicated that an oxazolone, i.e. 13 in Scheme 4, is most probably the first 
intermediate from which the imino lactones 12 and the chloro acids 11 are formed. 
Therefore, we decided to prepare 9g-i with different protecting groups, which could 
potentially allow the deprotection and isolation of  the oxazolone with a free hydroxy 
group as a precursor for the cyclization to give A. 
We planned to prepare 9g-i analogously to 9d (Scheme 2). The benzyl, 
(benzyloxy)methyl (Bom) and Fmoc protecting group could be introduced before the 
oxidative clevage of the double bond and yield the protected acids of type 8, which could 
then be reacted with 2H-azirin-3-amine 10b to give the protected diamides 9. Because of 
the instability of the protecting group under the oxidation conditions, direct protection of 
the hydroxy amide 4d was preferred (Scheme 6). Unfortunately, the deprotection failed in 
all cases. 
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Since the DAC method failed to give cyclic depsipeptides, we attempted to synthesize the 
hydroxy esters of type 17 from amides 4 and to subject them to the NaH cyclization 
procedure, described earlier [16][17]. Unexpectedly, treatment of 4d and 4e with HCl gas 
in toluene containing 20% EtOH as an external nucleophile did not yield the desired 
esters 17, but gave as the main products the imino lactone esters 14 in moderate yields 
together with the corresponding ω-chloro esters 18 (Scheme 7). 
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 16
Further experiments with 4d in the presence of MeOH showed that the ester could also be 
formed directly from the imino lactone 12a, either under DAC conditions or by treatment 
with CH2N2 (Schemes 5 and 7). 
If instead of the hydroxy amides 4, the protected alcohols 9d or 9f were subjected to the 
DAC conditions in the presence of MeOH, the unprotected linear esters 17 were formed 
(Scheme 8). We believe that again oxazolones are the intermediates and since the OH 
group in 9 is protected, it is to be expected that protected oxazolones of type 16 (Scheme 
6) are the intermediates. Nucleophilic addition of MeOH to the oxazolone, followed by 
ring opening, leads to the ester group in 17. The deacetylation could be explained by 
trans-esterification, via formation of AcOMe, which is a common reaction under acidic 
conditions.  
Scheme 8 
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The esters 17 were subjected to the conditions of the NaH-catalyzed cyclization, i.e. they 
were treated with NaH in toluene at 80o [16][27], but no cyclic products were obtained. 
As in previous studies [16][17], the rigidity of the amide bond was suggested as the 
reason for the failure. Therefore, the aminoketone 19 was synthesized, as depicted in 
Scheme 9, and subjected to the same reaction conditions. Again, no cyclic products could 
be identified in the mixture. 
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If indeed the formation of the cyclic products 12 and 14 occurs via the attack of the OH 
group at the imminium C-atom of the oxazolone 12 (see Scheme 4, path b), α-substitution 
in the hydroxy diamide 4 might present sufficient steric hindrance in order to direct the 
nucleophilic attack onto the ester group (Scheme 4, path a). Therefore, the amides 4g and 
4h were prepared analogously to Scheme 2. Treatment of amides 4g and 4h with HCl gas 
in toluene at 100o (DAC conditions) yielded imino lactones as sole products (Scheme 10).  
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Unlike their analogues 12a-c, compounds 12g,h are stable in solution. The higher 
substitution of the ring apparently stabilizes it, i.e. the gem-dimethyl effect, (Thorpe-
Ingold effect [28]) makes the ring opening thermodynamically unfavorable. Thanks to 
their stability in solution, crystals suitable for an X-ray crystal structure determination 
could be grown for both hydrochlorides 12g and 12h (Fig. 4). 
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a)   
 
b) 
 
Fig. 4. ORTEP Plots [24] of the molecular structures of a) 12g and b) 12h (arbitrary 
numbering of the atoms; 50% probability ellipsoids) 
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Since the space group of 12g is centrosymmetric, the compound in the crystal is racemic. 
The OH group forms a H-bond with a neighboring chloride ion, while the imminium 
group forms a H-bond with a different chloride ion.  Thus, each chloride ion accepts two 
H-bonds. These interactions link two cations and two anions in a cyclic manner into a 
tetrameric unit and can be described by a graph set motif [25] of R24(14). 
Similar H-bonding interactions occur in 12h, but this time the interactions link the ions 
into extended chains, which run parallel to the [1 0 0] direction and can be described by a 
graph set motif of C12(7). 
 
Conclusions 
When γ-hydroxy diamides 4 were subjected to the DAC reaction conditions, neither the 
8-membered nor the 16 membered depsipeptides were formed. Depending on the work-
up procedure, either the chlorinated acids 11 or the imino lactone hydrochlorides 12 with 
a carboxyl group were obtained as the sole products in good yields. Both products are 
formed via the intermediate oxazolones by an attack of the OH group at the iminium C-
atom, instead of at the carbonyl group of the oxazolone (Scheme 4). This attack leads to 
the five-membered ring, instead of the desired eight-membered ring. The former are 
obviously more stable than the latter. 
Compounds 12, with α-H atoms next to the carbonyl group, are unstable in solution and 
isomerize to the corresponding ω-chloro acids 11. Increased substitution of the imino 
lactone stabilizes the five membered ring and prevents isomerization. A few other 
cyclization methods were also tried, but they all failed to give cyclic depsipeptides. 
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Experimental Part 
 
1. General. See [16]. 
 
2. Starting Materials. 2,2,N,N-Tetramethyl-2H-azirin-3-amine (10a), 2,2,N-trimethyl-N-
phenyl-2H-azirin-3-amine (10b), and N,N-dimethyl-1-azaspiro[2.4]hept-1-en-2-amine 
(10c)  were prepared according to standard procedures (cf. [16] and refs. cited therein). 
2,2-Dimethylpent-4-enal (5a) was prepared from isobutyraldehyde according to Noack et 
al. [29], 2-phenylpent-4-en-1-ol (6c) was obtained from 2-phenylpropanal by following 
the method of  Iqbal et al. [30], and 2-methyl-2-phenylpent-4-enal (5d) was synthesized 
from 2-phenylpropanal analogously to 5a. All spectra were in accordance with literature 
data [31]. 2,2,3-Trimethylpent-4-enal (5e) and 2,2,3,3-tetramethylpent-4-enal (5f) were 
prepared according to Brannock et al. [32] from crotyl bromide and 1-bromo-3-
methylbut-2-ene, respectively. 1-Bromo-4-hydroxy-3,3-dimethylbutan-2-one (23) was 
synthesized according to  Mihelcic et al. [33]. All other products used were commercially 
available. 
3. Preparation of Pent-4-enyl Acetates. General Procedure 1 (GP 1). To a soln. of the 
corresponding pent-4-enal 5 (5 mmol) in MeOH (20 ml) at 0o, NaBH4 (760 mg, 20 
mmol) was added in small portions within 20 min, then the mixture was allowed to warm 
to r.t. and was stirred for a total of 1 h. The solvent was evaporated i.v. and the residue 
dissolved in H2O. Extraction with Et2O (5 × 30 ml), drying (MgSO4) and evaporation i.v. 
yielded the pent-4-en-1-ols 6, which were acetylated without further purification. For this 
purpose, 6 (5 mmol) was dissolved in Et2O (50 ml) and pyridine (0.81 ml, 10 mmol) was 
added. The mixture was heated to reflux and a soln. of Ac2O (0.41 ml, 5.5 mmol) in Et2O 
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(10 ml) was added dropwise within 20 min. The mixture was stirred under reflux for 
another 1.5 h, cooled, the salt was filtered off, the org. layer washed with 10% aq. CuSO4 
soln. and brine, dried (MgSO4), evaporated i.v. and purified by column chromatography 
(CC, SiO2) to yield the desired pent-4-enyl acetates 7. 
3.1. 2,2-Dimethylpent-4-enyl Acetate (7a). According to GP 1 from 2,2-dimethylpent-4-
enal (5a, 560 mg, 5 mmol), CC (hexane/Et2O 10:1). Yield: 593 mg, 79% of 7a as a 
colorless oil. All spectra were in accordance with literature data [34]. 
3.2. 2-Phenylpent-4-enyl Acetate (7c). To a soln. of 2-phenylpent-4-en-1-ol (6c, 5 mmol, 
810 mg) in Et2O (50 ml), pyridine (0.81 ml, 10 mmol) was added, the mixture was heated 
to reflux and then a soln. of Ac2O (0.71 ml, 5.5 mmol) in  Et2O (10ml) was added 
dropwise over 20 min. The reaction was stirred under reflux for another 1.5 h, cooled, the 
pyridinium acetate filtered off, the org. layer washed with 10% aq. CuSO4 soln. and 
brine, dried (MgSO4), evaporated i.v. and purified by  CC (hexane/Et2O 15:1) to  yield 
860 mg  (84%) of 7c. Colorless oil. 1H-NMR: 1.98 (s, MeCO); 2.24-2.41 (m, CH2); 2.91-
3.06 (m, PhCH); 4.11-4.26 (m, CH2O); 4.92-5.09 (m, CH2=CH); 5.62-5.83 (m, CH2=CH); 
7.12-7.39 (m, 5 arom. H). 13C-NMR: 20.8 (q, Me); 36.8 (t, CH2); 44.4 (d, CH); 67.6 (t, 
CH2O); 116.6 (t, CH2=CH); 126.7, 127.4, 128.3 (3d, 5 arom. CH), 135.6 (d, CH2=CH); 
141.3 (s, arom. C); 170.8 (s, C=O). ESI-MS: 205 (100, [M + H]+). 
3.3. 2-Methyl-2-phenylpent-4-enyl Acetate (7d). According to GP 1 from 2-methyl-2-
phenylpent-4-enal (5d, 870 mg, 5 mmol), CC (hexane/Et2O 20:1). Yield: 785 mg (72%) 
of 7d. Colorless oil. IR: 3075s, 2962vs, 2860vs, 1745vs, 1636s, 1482s, 1432s, 1386s, 
1334s, 1188s, 1076s, 1029s, 912m. 1H-NMR: 1.35 (s, Me); 2.05 (s, MeCO); 2.31-2.59 
(m, CH2); 4.13-4.28 (m,  CH2O); 4.87-5.11 (m, CH2=CH); 5.45-5.59 (m, CH2=CH); 7.14-
7.44 (m, 5 arom. H). 13C-NMR: 20.7, 22.5 (2q, 2 Me); 41.0 (s, C); 43.4 (t, CH2); 71.4 (t, 
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CH2O); 117.8 (t, CH2=CH); 126.1, 127.7, 128.1 (3d, 5 arom. CH); 133.3 (d, CH2=CH); 
144.3 (s, arom. C); 170.9 (s, C=O). ESI-MS: 219 (100, [M + H]+). 
3.4. 2,2,3-Trimethylpent-4-enyl Acetate (7e). According to GP 1, from 2,2,3-
trimethylpent-4-enal (5e, 5 mmol, 630 mg), CC (hexane/Et2O 10:1). Yield: 604 mg 
(71%) of 7e. Colorless oil. IR: 3077w, 2973vs, 2879s, 1744vs, 1637m, 1473m, 1377s, 
1036s, 914m. 1H-NMR: 0.86, 0.90 (2s, Me2C); 0.98 (d, J = 4.5, Me); 1.98 (s, MeCO); 
2.11-2,23 (m, MeCH); 3.36 (s, CH2O); 4.90-5.04 (m, CH2=CH); 5.74-5.92 (m, CH2=CH). 
13C-NMR: 14.6, 20.8, 21.6 (3q, Me, Me2C, MeCO); 36.5 (s, Me2C), 40.9 (d, MeCH); 70.4 
(t, CH2O); 114.1 (t, CH2=CH); 141.5 (d, CH2=CH); 171.8 (s, C=O). ESI-MS: 193 (100, 
[M + H]+). 
3.5. 2,2,3,3-Tetramethylpent-4-enyl Acetate (7f). According to GP 1, from 2,2,3,3-
tetramethylpent-4-enal (5f, 5 mmol, 700 mg), CC (hexane/Et2O 10:1). Yield: 717 mg 
(78%) of 7f. Colorless oil. IR: 3072m, 2964vs, 2909s, 1746vs, 1635m, 1473m, 1414m, 
1380s, 1315s, 1040s, 913s. 1H-NMR: 0.88, 0.99 (2s, 2 Me2C); 2.02 (s, MeCO); 3.90 (s, 
CH2O); 4.89-5.00 (m, CH2=CH); 5.87-5.96 (m, CH2=CH). 13C-NMR: 20.5 (q, Me2C); 
21.0 (q, MeCO); 22.6 (q, Me2C); 38.3, 40.8 (2s, 2 Me2C); 70.6 (t, CH2O); 112.0 (t, 
CH2=CH); 145.3 (d, CH2=CH); 171.3 (s, C=O). ESI-MS: 207 (100, [M + H]+). 
 
4. 4-Acetoxybutanoic Acids 8. General Procedure 2 (GP 2). To a soln. of pent-4-enyl 
acetates 7 (5 mmol) in MeCN/CCl4/H2O  2:2:3  (70 ml), NaIO4 (2.28 g, 20 mmol) was 
added under stirring. After 10 min, a catalytic amount of RuO2.H2O was added and the 
mixture stirred vigorously at r.t. for 4-12 h. Filtration of the white residue over celite, 
washing with CH2Cl2, extraction of the collected mother liquor with CH2Cl2, drying 
(MgSO4), evaporation i.v. and purification by CC  yielded  8  as colorless oils. 
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4.1. 4-Acetoxy-3,3-dimethylbutanoic Acid (8a). According to GP 2 from 7a (5 mmol, 780 
mg), 6 h, CC (CH2Cl2/MeOH 20:1). Yield: 625mg (73%) of 8a. Colorless oil. IR: 3284 s 
(br), 2969s, 1739vs, 1709vs, 1475w, 1379s, 1243s, 1041s, 926w. 1H-NMR: 0.98 (s, 
Me2C); 1.98 (s,  MeCO); 2.28 (s, CH2); 3.88 (s, CH2O); 9.83 (br. s, COOH). 13C-NMR: 
20.6 (q, Me); 24.9 (q, Me2C); 33.5 (s, Me2C), 42.8 (t, CH2); 71.6 (t, CH2O); 171.1 (s, 
C=O); 177.7 (s, COOH). ESI-MS: 197 (100, [M + Na]+). 
4.2. 4-Acetoxy-3-phenylbutanoic Acid (8c). According to GP 2, 7c (5 mmol, 1.020 g), 4 
h, CC (CH2Cl2/acetone 20:1). Yield: 678 mg (61%) of 8c. Colorless oil. 1H-NMR: 1.99 
(s, MeCO); 2.61-2.88 (m, CH2); 3.42-3.58 (m, PhCH); 4.09-4.36 (m, CH2O); 7.13-7.38 
(m, 5 arom. H.); 10.63 (br. s, COOH). 13C-NMR: 20.6 (q, MeCO); 37.1 (t, CH2), 40.7 (d, 
CH); 67.3 (t, CH2O); 127.2, 127.5, 128.6 (3d, 5 arom. CH); 139.8 (s, arom. C); 170.7 (s, 
C=O); 177.3 (s, COOH). ESI-MS: 245 (100, [M + Na]+). 
4.3. 4-Acetoxy-3-methyl-3-phenylbutanoic Acid (8d). According to GP 2 from 7d (5 
mmol, 1090 mg), 6 h, CC (CH2Cl2/MeOH 20:1). Yield: 861mg (73%) of 8d. Colorless 
oil. 1H-NMR: 1.31 (s, Me); 2.01 (s, MeCO); 2.28-2.36 (m, CH2); 4.18-4.45 (m, CH2O); 
7.08-7.38 (m, 5 arom. H). 13C-NMR: 20.9 (q, MeCO); 26.6 (q, Me); 31.1 (s, Me2C); 45.7 
(d, CH); 69.3 (t, CH2O); 127.3, 127.6, 128.9 (3d, 5 arom. CH); 141.2 (s, arom. C); 171.4 
(s, C=O); 176.1 (s, COOH). ESI-MS: 259 (100, [M + Na]+). 
4.4. 4-Acetoxy-2,3,3-trimethylbutanoic Acid (8e). According to GP 2 from  7e (5 mmol, 
850 mg ), 6 h, CC (CH2Cl2/MeOH 20:1). Yield: 771mg (82%) of 8e. Colorless oil. IR: 
3466 br. s, 2976s, 1738vs, 1710vs, 1467w, 1390s, 1245s, 1041s, 925w. 1H-NMR: 0.95, 
0.99 (2s, Me2C); 1.18 (d, J = 4.7,  MeCH); 2.00 (s, MeCO); 2.48 (q, J = 4.7, MeCH); 
3.89 (s, CH2O); 10.11 (br. s, COOH). 13C-NMR: 15.6, 20.6 (2q, 2 Me); 21.8, 22.1 (2q, 
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Me2C); 38.7 (s, Me2C); 45.1 (d, CH); 70.8 (t, CH2O); 171.0 (s, C=O); 181.3 (s, COOH). 
ESI-MS: 211 (100, [M + Na]+). 
4.5. 4-Acetoxy-2,2,3,3-tetramethylbutanoic Acid (8f). According to GP 2 from 7f (5 
mmol, 920 mg), 4 h, CC (CH2Cl2/MeOH 20:1). Yield: 524 mg (52%) of 8f. IR: 3290s 
(br), 2972s, 1743vs, 1477m, 1377m, 1248s, 1214w, 1040s, 1021w, 926w. 1H-NMR: 0.99, 
1.19 (2s, 2 Me2C); 2.03 (s, MeCO); 3.99 (s, CH2O); 9.63 (br. s, COOH). 13C-NMR: 20.6 
(q, MeCO); 21.1, 21.4 (2s, 2 Me2C); 38.3, 46.9 (2s, 2 Me2C); 70.1 (t, CH2O); 171.1 (s, 
C=O); 183.3 (s, COOH). CI-MS: 203 (38, [M + H]+), 143 (100, [M - MeCO]+). 
 
5. Coupling of 8 with 2H-Azirin-3-amines 10. General Procedure 3 (GP 3). Acids 8 were 
taken up in dry THF (20 ml) and the corresponding aminoazirine 10 was added dropwise. 
The mixture was stirred overnight at r.t., the solvent evaporated i.v. and the residue 
purified by CC to yield acetoxy diamides  9. 
5.1. 3-[1-Methyl-1-(N,N-dimethylcarbamoyl)ethylcarbamoyl]-2,2-dimethylpropyl Acetate 
(9a). According to GP 3 from  8a (348 mg, 2 mmol) in dry THF (20 ml) and 10a (235 
mg, 2.1 mmol), CC (CH2Cl2/MeOH 30:1). Yield: 509 mg (89%) of 9a. White powder. 
M.p. 99.1-99.2o. 1H-NMR: 0.98, 1.52 (2s, 2 Me2C); 2.05 (s, MeCO); 2.10 (s, CH2); 3.08 
(br. s, Me2N); 3.98 (s, CH2O); 7.12 (s, NH). 13C-NMR: 20.9 (q, MeCO); 24.5, 24.7 (2q, 2 
Me2C); 34.1 (s, Me2C); 38.2 (q, Me2N); 45.5 (t, CH2); 56.8 (s, Me2C); 71.8 (t, CH2O); 
169.4, 171.2, 173.2 (3s, 3 C=O). ESI-MS: 309 (100, [M + Na]+]). 
5.2. 3-[1-(N,N-Dimethylcarbamoyl)cyclopentylcarbamoyl]-2,2-dimethylpropyl Acetate 
(9c). According to GP 3 from  8a (348 mg, 2 mmol) in dry THF (20 ml) and 10c (290 
mg, 2.1 mmol), CC (CH2Cl2/MeOH 20:1). Yield: 549 mg (88%) of 9c. White powder. 
M.p. 139.0-140.2o. 1H-NMR: 1.02 (s, Me2C); 1.66-1.78, 1.83-1.93 (2m, 4 CH2); 2.07 (s, 
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MeCO); 2.18-2.26 (m, CH2); 2.98 (br. s, Me2N); 3.96 (s, CH2O); 6.41 (br. s, NH). 13C-
NMR: 21.0 (q, MeCO); 22.4 (t, CH2); 24.6 (q, Me2C); 34.3 (t, CH2); 35.7 (s, Me2C); 38.2 
(q, Me2N); 44.3 (t, CH2); 66.8 (s, Me2C); 71.9 (t, CH2O); 169.8, 171.4, 172.5 (3s, 3 
C=O). CI-MS: 313 (40, [M + H]+), 268 (100, [M - NMe2]+), 
5.3. 3-[1-Methyl-1-(N-methyl-N-phenylcarbamoyl)ethylcarbamoyl]-2,2-dimethylpropyl 
Acetate (9d). According to GP 3 from 8a (348 mg,  2 mmol) in dry THF (20 ml) and 10b 
(365 mg, 2.1 mmol), CC (CH2Cl2/MeOH 40:1). Yield: 584 mg (84%) of 9d. White 
powder. M.p. 94.1-95.8o. 1H-NMR: 0.99, 1.48 (2s, 2 Me2C); 2.03 (s, MeCO); 2.12 (s, 
CH2); 3.26 (s, MeN); 3.91 (s, CH2O); 6.38 (s, NH); 7.21-7.43 (m, 5 arom. H). 13C-NMR: 
20.9 (q, MeCO); 24.4, 26.0 (2q, 2 Me2C); 34.0 (s, Me2C); 41.5 (q, MeN); 46.0 (t, CH2); 
58.3 (s, Me2C); 71.7 (t, CH2O); 127.9, 128.2, 129.3 (3d,5 arom. CH); 144.5 (s, arom. C); 
169.6, 171.2, 173.4 (3s, 3 C=O). ESI-MS: 371 (100, [M + Na]+]). 
5.4. 3-[1-Methyl-1-(N-methyl-N-phenylcarbamoyl)ethylcarbamoyl]-2-phenylpropyl 
Acetate (9e). According  to GP 3 from 8c (444 mg, 2 mmol) in dry THF (20 ml) and 10b 
(365 mg, 2.1 mmol), CC (CH2Cl2/MeOH 50:1). Yield: 689 mg (87%) of 9e. White 
powder. M.p. 133.3-134.2o. 1H-NMR: 1.32, 1.38 (2s, Me2C); 2.09 (s, MeCO); 2.18-2.25, 
2.43-2.50 (2m, CH2); 3.20-3.26 (m, MeN, CH); 3.72-3.77 (m, CH2O); 5.97 (s, NH); 7.17-
7.36 (m, 10 arom. H). 13C-NMR: 21.1 (q, MeCO); 26.1, 26.2 (2q, Me2C); 40.9 (t, CH2); 
41.3 (q, MeN); 44.5 (d, CH); 58.1 (s, Me2C); 67.0 (t, CH2O); 126.9, 127.5, 127.9, 128.6, 
129.3 (5d, 5 arom. CH); 141.8, 144.4 (2s, 2 arom. C); 169.9, 171.0, 173.0 (3s, 3 C=O). 
ESI-MS: 419 (100, [M + Na]+). 
5.5. 3-[1-Methyl-1-(N-methyl-N-phenylcarbamoyl)ethylcarbamoyl]-2-methyl-2-
phenylpropyl Acetate (9f). According to GP 3 from 8d (472 mg, 2 mmol) in dry THF (20 
ml) and 10b (365 mg, 2.1 mmol), CC (CH2Cl2/MeOH 50:1). Yield: 689 mg (84%) of 9f. 
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White powder. M.p. 135.1-136.6o. 1H-NMR: 1.08, 1.16, 1.36 (3s, Me, Me2C); 2.08 (s, 
MeCO); 2.11-2.17 (m, CH2); 3.16 (s, MeN); 4.21 (s, CH2O); 5.64 (s, NH); 7.09-7.41 (m, 
10 arom. H). 13C-NMR: 20.8 (q, MeCO); 22.4, 26.1, 26.6 (3q, Me, Me2C); 30.8 (s, 
Me2C); 41.1 (q, MeN); 46.3 (t, CH2); 57.4 (s, Me2C); 71.1 (t, CH2O); 126.1, 127.6, 127.9, 
128.5, 128.9, 129.3 (6d, 10 arom. CH); 143.6, 144.8 (2s, 2 arom. C); 168.9, 170.8, 172.9 
(3s, 3 C=O).  CI-MS: 411 (42, [M + H]+), 304 (100, [M – Me(Ph)N]+), 175 (21). 
5.6. 3-[1-Methyl-1-(N-methyl-N-phenylcarbamoyl)ethylcarbamoyl]-2,2-dimethylbutyl 
Acetate (9g). According to GP 3 from 8e (372 mg, 2 mmol) in dry THF (20 ml) and 10b 
(365 mg, 2.1 mmol), CC (CH2Cl2/MeOH 50:1). Yield: 637 mg (88%) of 9g. White 
powder. M.p. 139.6-140.9o. 1H-NMR: 0.99, 1.00 (2s, Me2C); 1.05 (d, J = 3.9,  MeCH); 
1.40, 1.41 (2s, Me2C); 2.05-2.12 (m, MeCO, CH); 3.19 (s, MeN); 3.86 (q, CH2O); 6.66 
(s, NH); 7.14-7.46 (m, 5 arom. H). 13C-NMR: 12.2 (q, Me); 20.8 (q, MeCO); 21.6, 22.4, 
24.8, 25.0 (4q, 2 Me2C); 35.9 (s, Me2C); 41.4 (q, MeN); 46.4 (d, CH); 58.5 (s, Me2C); 
71.3 (t, CH2O); 128.0, 128.4, 129.3 (3d, 5 arom. CH); 144.1 (s, arom. C); 170.9, 172.7, 
173.7 (3s, 3 C=O). ESI-MS: 385 (100, [M + Na]+). 
5.7. 3-[1-Methyl-1-(N-methyl-N-phenylcarbamoyl)ethylcarbamoyl]-2,2,3-trimethylbutyl 
Acetate (9h). According to GP 3 from 8f (404 mg, 2 mmol) in dry THF (20 ml) and 10b 
(365 mg, 2.1 mmol), CC (CH2Cl2/MeOH 50:1). Yield: 684 mg (91%) of 9h. White 
powder. M.p. 119.9-120.9o. 1H-NMR: 0.93, 1.11, 1.47 (3s, 3 Me2C); 2.04 (s, MeCO); 
3.26 (s, MeN); 3.98 (s, CH2O); 7.04 (s, NH); 7.18-7.41 (m, 5 arom. H). 13C-NMR: 21.0, 
21.7, 24.9 (3q, 3 Me2C); 38.6 (s, Me2C); 41.7 (q, MeN); 47.2, 58.8 (2s, 2 Me2C); 70.7 (t, 
CH2O); 128.3, 128.6, 129.5 (3d, 5 arom. CH); 144.1 (s, arom. C); 171.1, 174.3, 176.9 (3s, 
3 C=O). ESI-MS: 415 (20, [M + K]+), 399 (100, [M + Na]+), 377 (60, [M + H]+). Anal. 
calc. for C21H32N2O4 (376.50): C 66.99, H 8.57, N 7.44; found: C 66.35, H 8.28, N 7.15. 
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6. Deprotection of 9 to give Hydroxydiamides 4. General Procedure 4 (GP 4).  The 
amides 9 were treated with 4 equiv. of LiOH in THF/H2O 2:1 at r.t. for 4-12 h. 
Evaporation of the solvent i.v., extraction of the residue with CH2Cl2, drying (MgSO4), 
evaporation i.v. and washing with Et2O yielded the hydroxydiamides 4 as white powders, 
which were used without further purification. 
6.1. 4-Hydroxy-3,3-dimethyl-N-[1-methyl-1-(N,N-dimethylcarbamoyl)ethyl]butanamide 
(4a). According to GP 4 from 9a (858 mg, 3 mmol), 4 h. Yield: 677 mg (93%) of 4a. 
White powder. M.p. 138.6-139.9o. 1H-NMR: 0.99, 1.64 (2s, Me2C); 2.14 (s, CH2); 3.12 
(br. s, Me2N); 3.91 (s, CH2O); 7.02 (s, NH). 13C-NMR: 24.6, 24.8 (2q, 2 Me2C); 34.6 (s, 
Me2C); 38.8 (q, Me2N); 45.4 (t, CH2); 56.8 (s, Me2C); 71.3 (t, CH2O); 171.4, 173.0 (2s, 2 
C=O). CI-MS: 244 (32, [M + H]+]), 201 (100, [M - Me2N]+]). 
6.2. 4-Hydroxy-N-[1-methyl-1-(N,N-dimethylcarbamoyl)ethyl]butanamide (4b). A soln. 
of sodium 4-hydroxy-butanate (1.0 g, 7.9 mmol) in H2O (10 ml) was acidified with 3N 
HCl. Extraction with AcOEt (5 × 30 ml), drying (MgSO4), evaporation of the solvent i.v. 
yielded 520 mg (63%) of 4-hydroxybutanoci acid as a viscous fluid, which was used 
without further purification. All spectra were in accordance with the data in [35]. 4-
Hydroxybutanoic acid (600 mg, 5.77 mmol) was dissolved in dry THF (20 ml) and 10a 
(711 mg, 6.35 mmol, 1.1 equiv.)  was added dropwise. The mixture was stirred overnight 
at r.t., the solvent evaporated i.v. and the residue purified by CC (CH2Cl2/MeOH 10:1). 
Yield: 1134 mg (90%) of 4b. White solid. M.p. 124.6-125.3o. 1H-NMR: 1.48 (s, Me2C); 
1.73-1.82 (m, CH2); 2.08 (t, J = 6.2, CH2); 3.26 (s, Me2N); 3.65 (t, J = 6.2, CH2O); 6.38 
(s, NH); 7.24-7.32 (m, 5 arom. H). 13C-NMR: 24.4 (t, CH2); 26.0 (q, Me2C); 41.5 (q, 
Me2N); 46.0 (t, CH2); 58.3 (s, Me2C); 71.7 (t, CH2O); 127.9, 128.2, 129.3 (3d, 5 arom. 
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CH); 144.5 (s, arom. C); 171.2, 173.4 (2s, 2 C=O). CI-MS: 279 (85, [M + H]+), 172 (100, 
[M - Me2N]+). 
6.3. 4-Hydroxy-3,3-dimethyl-N-[1-(N,N-dimethylcarbamoyl)cyclopentyl]butanamide 
(4c). According to GP 4 from 9c (936 mg, 3 mmol), 6 h. Yield: 738 mg (91%) of 4c. 
White powder. M.p. 138.4-139.9o. 1H-NMR: 0.99 (s, Me2C); 1.62-1.76, 1.84-2.02 (2m, 4 
CH2); 2.21-2.39 (m, CH2); 3.03 (br. s, Me2N); 3.38 (s, CH2O); 6.61 (br. s, NH). 13C-
NMR: 24.4 (t, CH2); 25.2 (q, Me2C); 35.7 (s, Me2C); 37.3 (t, CH2); 37.9 (q, Me2N); 46.4 
(t, CH2); 66.6 (s, C); 71.9 (t, CH2O); 172.2, 172.7 (2s, 2 C=O). ESI-MS: 309 (10, [M + 
K]+), 293 (100, [M + Na]+). 
6.4. 4-Hydroxy-3,3-dimethyl-N-[1-methyl-1-(N-methyl-N-phenylcarbamoyl) 
ethyl]butanamide (4d). According to GP 4, from 9d (1044 mg, 3 mmol), 6 h. Yield: 845 
mg (92%) of 4d. White powder. M.p. 138.4-139.9o. 1H-NMR: 0.92, 1.44 (2s, 2 Me2C); 
2.13 (s, CH2); 3.22 (s, MeN); 3.91 (s, CH2O); 6.32 (s, NH); 7.16-7.41 (m, 5 arom. H). 
13C-NMR: 25.2, 26.0 (2q, 2 Me2C); 35.6 (s, Me2C); 41.3 (q, MeN); 47.2 (t, CH2); 58.2 (s, 
Me2C); 71.4 (t, CH2O); 127.9, 128.2, 129.2 (3d, 5 arom. CH); 144.3 (s, arom. C); 171.6, 
173.1 (2s, 2 C=O).  ESI-MS: 345 (20, [M + K]+), 329 (100, [M + Na]+). Anal. calc. for 
C17H26N2O3 (306.41): C 66.64, H 8.55, N 9.14; found: C 66.36, H 8.49, N 8.97. 
6.5. 4-Hydroxy-N-[1-methyl-1-(N-methyl-N-phenylcarbamoyl)ethyl]-3-phenyl 
butanamide (4e). According to GP 4, from 9e (1188 mg, 3 mmol), 8 h. Yield: 934 mg 
(88%) of 4e. White powder. M.p. 129.0-129.9o. 1H-NMR: 1.28, 1.35 (2s, Me2C); 2.11-
2.21, 2.34-2.46 (2m, CH2); 3.17 (br. s, MeN, CH); 3.64-3.79 (m, CH2O); 5.96 (s, NH); 
7.10-7.41 (m, 10 arom. H). 13C-NMR: 26.1, 26.2 (2q, Me2C); 40.9 (q, MeN); 41.2 (t, 
CH2); 44.5 (d, CH); 58.2 (s, Me2C); 67.1 (t, CH2O); 126.8, 127.5, 127.9, 128.6, 129.3 
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(5d, 10 arom. CH); 141.7, 144.4 (2s, 2 arom. C); 171.1, 173.0 (2s, 2 C=O). CI-MS (i-
butane): 355 (100, [M + H]+). 
6.6. 4-Hydroxy-N-[1-methyl-1-(N-methyl-N-phenylcarbamoyl)ethyl]-3-methyl-3-
phenylbutanamide (4f). According to GP 4 from 9f (820 mg, 2 mmol), 12 h. Yield: 587 
mg (90%) of 4f. White powder. M.p. 121.9-123.3o. 1H-NMR: 1.22, 1.23, 1.24 (3s, Me, 
Me2C); 2.11-2.19, 2.31-2.38 (2m, CH2); 3.15 (s, MeN); 3.51-3.59, 3.83-3.89 (2m, CH2O); 
5.84 (s, NH); 7.11-7.43 (m, 10 arom. H). 13C-NMR: 23.6, 26.1, 26.2 (3q, Me, Me2C); 
41.4 (q, Me2N); 42.7 (s, Me2C); 47.4 (t, CH2); 58.1 (s, Me2C); 70.6 (t, CH2O); 126.1, 
126.5, 127.8, 128.5, 129.3 (5d, 10 arom. CH); 144.5, 145.5 (2s, 2 arom. C); 170.9, 173.0 
(2s, 2 C=O). CI-MS (i-butane): 327 (80, [M + H]+), 221 (100, [M - Ph(Me)N]+). 
6.7. 4-Hydroxy-2,3,3-trimethyl-N-[1-methyl-1-(N-methyl-N-phenylcarbamoyl) 
ethyl]butanamide (4g). According to GP 4 from 9g (724 mg, 2 mmol), 4 h. Yield: 576 
mg (90%) of 4g. White powder. M.p. 124.2-126.3o. 1H-NMR: 1.00 (s, Me2C); 1.09 (d, J 
= 4.6, MeCH); 1.40, 1.42 (2s, Me2C); 2.08 (q, J = 4.6, CH); 3.18 (s, MeN); 3.51-3.59 (m, 
CH2O); 6.96 (s, NH); 7.12-7.42 (m, 5 arom. H). 13C-NMR: 12.7 (q, Me); 23.4, 24.2, 25.0 
(3q, 3 Me2C); 37.6 (s, Me2C); 41.7 (q, MeN); 49.9 (d, CH); 58.9 (s, Me2C); 69.3 (t, 
CH2O); 128.4, 128.6, 129.5 (3d, 5 arom. CH); 143.9 (s, arom. C); 173.8, 175.6 (2s, 2 
C=O). ESI-MS: 343 (100, [M + Na]+). 
6.8. 4-Hydroxy-2,2,3,3-tetramethyl-N-[1-methyl-1-(N-methyl-N-phenylcarbamoyl)ethyl]-
butanamide (4h). According to GP 4, from 9h (752 mg, 2 mmol), 4 h. Yield: 608 mg 
(91%) of 9h. White powder. M.p. 129.9-131.3o. 1H-NMR: 0.88, 1.15, 1.46 (3s, 3 Me2C); 
3.29 (s, MeN); 3.44 (s, CH2O); 6.48 (s, NH); 7.23-7.42 (m, 5 arom. H). 13C-NMR: 21.5, 
21.9, 24.6 (3q, 3 Me2C); 39.6 (s, Me2C); 41.6 (q, MeN); 47.6, 58.9 (2s, 2 Me2C); 70.7 (t, 
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CH2O); 128.2, 128.4, 129.4 (3d, 5 arom. CH); 143.9 (s, arom. C); 173.9, 177.8 (2s, 2 
C=O). ESI-MS: 357 (100, [M + Na]+). 
 
7. Attempted Direct Amide Cyclizations of Amides 4. General Procedure 5 (GP 5). A 
suspension of 4 (0.5 mmol) in dry toluene (50 ml) was heated to 100o and HCl gas was 
bubbled through the suspension for 4-6 min. Then, the mixture was allowed to cool to r.t. 
while bubbling N2 through it (ca. 20 min). The solvent was evaporated, the white residue 
was washed with CH2Cl2 (3 × 15 ml) and dried in h.v. to yield imino lactone 
hydrochlorides 12 as white powders.  
General Procedure 6 (GP 6).  A suspension of 4 was treated as in GP 5. The solvent was 
evaporated, and the oily residue was purified by CC to yield the ω-chloro acids 11. 
7.1. 2-[(4,4-Dimethyltetrahydrofuran-2-yliden)amino]-2-methylpropanoic Acid 
Hydrochloride (12a). According to GP 5 from 4d (153 mg, 0.5 mmol). Yield: 101 mg 
(84%). M.p. 158.3-159.1o. IR: 3431w, 2938s, 2804s, 1735vs, 1678vs, 1529s, 1414m, 
1319m, 1194s, 1166s, 1003m, 946m, 754m. 1H-NMR ((D6)DMSO): 1.15, 1.56 (2s, 2 
Me2C); 3.13 (s, CH2); 4.56 (s, CH2O); 13.2 (br. s, COOH). 13C-NMR ((D6)DMSO): 23.5, 
24.1 (2q, 2 Me2C); 38.0, 60.1 (s, Me2C); 88.0 (t, CH2O); 162.0 (C=N); 180.2 (s, C=O). 
CI-MS: 200 (100, [M - Cl]+).  
7.2. 2-[(3,4,4-Trimethyltetrahydrofuran-2-yliden)amino]-2-methylpropanoic Acid 
Hydrochloride (12g). According to GP 5 from 4g (160 mg, 0. 5mmol). Yield: 78 mg 
(73%). M.p. 152.4-153.6o. IR: 3386w, 2986s, 2776s, 1739vs, 1671vs, 1514m, 1478s, 
1240m, 1178s, 1165s, 997s, 773m. 1H-NMR ((D6)DMSO): 1.08 (d, J = 4.9, Me); 1.21, 
1.48 (2s, 2 Me2C); 2.18 (q, J = 4.9, CH); 4.42 (s, CH2O); 10.0 (br. s, COOH). 13C-NMR 
((D6)DMSO): 12.0 (q, Me); 21.1, 22.2 (2q, 2 Me2C); 36.5 (s, Me2C); 46.1 (d, CH); 58.2 
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(s, Me2C); 87.2 (t, CH2O); 163.1 (C=N); 178.0 (s, C=O). CI-MS (i-butane): 214 (100, [M 
- Cl]+), 108 (25). Anal. calc. for C11H20NO3Cl (249.74): C 52.90, H 8.07, N 5.61; found C 
50.55, H 7.87, N 5.25. 
7.3. 2-[(3,3,4,4-Tetramethyltetrahydrofuran-2-yliden)amino]-2-methylpropanoic Acid 
Hydrochloride (12h). According to GP 5  from 4h (167 mg, 0.5 mmol). Yield: 79 mg 
(78%), M.p. 157.0-157.6o. IR: 3390w, 3024s, 2938s, 2778s, 1738vs, 1669vs, 1476s, 
1400s, 1313m, 1178s, 998m, 880m, 772m. 1H-NMR ((D6)DMSO): 0.97, 1.26, 1.56 (3s, 3 
Me2C); 4.58 (s, CH2O); 12.9 (br. s,  COOH). 13C-NMR ((D6)DMSO):  21.6, 22.5, 26.1 
(3q, 3 Me2C); 42.8, 46.6, 60.7 (3s, 3 Me2C); 86.8 (t, CH2O); 168.1 (C=N); 183.2 (s, 
C=O). ESI-MS: 228 (100, [M + Na]+). 
7.4. 2-(4-Chloro-3,3-dimethylbutanoylamino)-2-methylpropanoic Acid (11a). According 
to GP 6  from 4a (122 mg, 0.5 mmol) or from  4d (153 mg, 0.5 mmol), CC 
(CH2Cl2/acetone 10:1). Yield: 57 mg (48%) of 11a from 4a and 62 mg (52%) from 4d. 
White powder. M.p. 116.1-117.3o. IR: 3356vs, 2981s, 2605m, 1717vs, 1620vs, 1548vs, 
1473s, 1393s, 1294m, 1221s, 1158s, 1023m, 895m, 791s. 1H-NMR ((D6)DMSO): 1.00, 
1.31 (2s, 2 Me2C); 2.09 (s, CH2); 3.59 (s, CH2Cl); 7.12 (br. s, NH); 12.9 (br. s, COOH). 
13C-NMR ((D6)DMSO): 24.9, 25.8 (2q, 2 Me2C); 36.6 (s, Me2C); 44.9 (t, CH2); 55.3 (t, 
CH2Cl); 60.3 (s, Me2C); 172.1, 181.1 (2s, 2 C=O). ESI-MS: 260 (32, [M(37Cl) + Na]+), 
258 (100, [M(35Cl) + Na]+). 
7.5. 2-(4-Chlorobutanoylamino)-2-methylpropanoic Acid (11b). According to GP 6 from 
4b (140 mg, 0.5 mmol), CC (CH2Cl2/acetone 10:1). Yield: 62 mg (66%) of 11b. White 
solid. M.p. 111.9-113.1o. IR: 3318vs, 2988s, 1721vs, 1623s, 156s, 1467s, 1399m, 1230m, 
1166s, 1050w, 945w, 787m. 1H-NMR: 1.57 (s, Me2C); 2.07-2.13 (m, CH2); 2.37 (t, J = 
6.1, CH2); 3.61 (t, J = 6.1, CH2Cl); 7.29 (br. s, NH). 13C-NMR : 24.7 (q, Me2C); 33.9 (t, 
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CH2); 44.4 (t, CH); 55.6 (t, CH2Cl); 59.6 (s, Me2C); 171.8, 176.6 (2s, 2 C=O). CI-MS: 
210 (10, [M(37Cl) + NH4]+), 208 (25, [M(35Cl) + NH4]+), 172 (100, [M - Cl]+). 
7.6. 1-[(4-Chloro-3,3-dimethylbutyl-1-oxo)amino]cyclopentanecarboxylic Acid (11c). 
According to GP 6 from 4c (135 mg, 0.5 mmol), CC (CH2Cl2:acetone 10:1). Yield: 69 
mg (53%) of 11c. White powder. M.p. 113.2-114.7o. 1H-NMR: 1.02, 1.09 (2s, Me2C); 
1.71-1.76, 1.94-2.02 (2m, 4 CH2); 3.22 (m, CH2); 3.63 (m, CH2Cl); 7.47 (br. s, NH). 13C-
NMR: 24.8 (t, CH2); 25.3 (q, Me2C); 36.3 (q, Me2C); 37.5, 44.7 (2t, 2 CH2); 55.0 (t, 
CH2Cl); 66.1 (s, Me2C); 171.7, 176.4 (2s, 2 C=O). CI-MS: 264 (28, [M(37Cl) + H]+), 262 
(72, [M(35Cl) + H]+), 226 (100, [M - Cl]+). 
7.7 2-(4-Chloro-3-phenylbutanoylamino)-2-methylpropanoic Acid (11d). According to 
GP 6  from 4e (184 mg, 0.5 mmol), CC (CH2Cl2/acetone 20:1). Yield: 51 mg (43%) of 
11d. White powder. M.p. 119.6-121.8o (decomp). IR: 3320vs, 2928s, 1722vs, 1626vs, 
1606s, 1557s, 1496s, 1442s, 1315s, 1260m, 1170s, 1079m, 752s, 696s. 1H-NMR: 1.36, 
1.39 (2s, Me2C); 2.53-2.60, 2.70-2.78 (m, CH2); 3.48-3.52 (m, PhCH); 3.85-3.91 (m, 
CH2Cl);  7.24-7.32 (m, 5 arom. H); 7.45 (br. s, NH); 12.3 (br. s, COOH). 13C-NMR: 24.8, 
25.3 (2q, 2 Me2C); 40.2 (t, CH2); 45.3 (d, CH); 55.3 (t, CH2Cl); 59.6 (s, Me2C); 127.6, 
128.7, 129.0 (3d, 5 arom. CH); 142.3 (s, arom. C); 171.1, 179.1 (2s, 2 C=O). CI-MS: 286 
(15, [M(37Cl) + H]+), 284 (39, [M(35Cl) + H]+), 248 (100, [M - Cl]+). 
 
8. Synthesis of dipeptide esters. General Procedure 7 (GP 7).  A suspension of 4 (0.5 
mmol) in a mixture of dry toluene (50 ml) and alcohol (5 ml) was heated to reflux and 
HCl gas was bubbled through the suspension for 6 min. Then, the mixture was allowed to 
cool to r.t. while bubbling N2 through it (ca. 20 min). The solvent was evaporated, and 
the oily residue was purified by CC to yield the products as colorless oils. 
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General Procedure 8 (GP 8). To solid  12a (117 mg, 0.5 mmol), a 0.5 M soln. of CH2N2 
in Et2O (1 ml, 0.5 mmol) was added dropwise at 0o. After the disappearance of the yellow 
color, another 1 ml of CH2N2 was added, the mixture allowed to warm up to r.t., stirred 
for 15 min, filtered, and the solvent evaporated  i.v. The white solid 14a was used without 
further purification. 
8.1. Methyl 2-[(4,4-Dimethyltetrahydrofuran-2-yliden)amino]-2-methylpropanoate (14a). 
Accordig to GP 7 from 4d (153 mg, 0.5 mmol), 5 ml of MeOH, CC (CH2Cl2/acetone 
20:1). Yield: 50 mg (43%) of 14a. White solid. M.p. 88.6-89.8o. IR: 2961s, 2876m, 
1736vs, 1706vs, 1567s, 1360m, 1271s, 1143s, 101m, 919m, 731s. 1H-NMR ((D6)DMSO): 
1.05, 1.28 (2s, 2 Me2C); 2.24 (s, CH2); 3.56 (s, MeO); 3.83 (s, CH2O). 13C-NMR 
((D6)DMSO): 23.6, 25.8 (2q, Me2C); 36.6 (s, Me2C); 42.4 (t, CH2); 50.1 (q, MeO); 58.9 
(s, Me2C); 80.3 (t, CH2O); 162.2 (s, C=N); 175.3 (s, C=O). CI-MS: 231 (100, [M + 
NH4]+). 
An experiment according to GP 8 yielded 113 mg (98%) of 14a  as a white solid. 
8.2. Ethyl 2-[(4,4-Dimethyltetrahydrofuran-2-yliden)amino]-2-methylpropanoate (14b). 
According to GP 7 from 4d (153 mg, 0.5 mmol), 5 ml of EtOH, after CC 
(CH2Cl2/acetone 20:1). Yield: 49 mg (43%) of 14b and 51 mg of ethyl 2-(4-chloro-3,3-
dimethylbutanoylamino)-2-methylpropanoate 18b (38%) as colorless oils. 
14b: IR: 2965vs, 2893s, 1714vs, 1697vs, 1468s, 1380s, 1273s, 1166s, 1035m, 911m, 
731s. 1H-NMR: 1.11 (s, Me2C); 1.21 (t, J = 7.1, MeCH2); 1.43 (s, Me2C); 2.33 (s, CH2); 
3.82 (s, CH2O); 4.18 (q, J = 7.1, MeCH2). 13C-NMR: 14.3 (q, Me); 25.1, 26.6 (2q, Me2C); 
37.1 (s, Me2C); 44.5 (t, CH2); 60.4 (t, MeCH2); 60.5 (s, Me2C); 81.9 (t, CH2O); 163.7 (s, 
C=N); 176.5 (s, C=O). ESI-MS: 477 (15, [2M + Na]+), 250 (100, [M + Na]+), 228 (12, [M 
+ H]+). 
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18b: 1H-NMR: 1.05 (s, Me2C); 1.16 (t, J = 7.2, MeCH2); 1.27 (s, Me2C); 2.24 (s, CH2); 
3.81 (s, CH2Cl); 4.02 (q, J = 7.2, MeCH2); 6.02 (br. s, NH). 13C-NMR: 14.2 (q, Me); 
24.7, 25.8 (2q, 2 Me2C); 35.8 (s, Me2C); 38.4 (t, CH2); 54.9 (t, CH2O); 61.3 (t, MeCH2); 
65.6 (s, Me2C); 170.4, 172.6 (2s, 2 C=O). ESI-MS: 288 (31), 286 (100, [M + Na]+). 
8.3. Methyl 2-Methyl-2-[(4-methyl-4-phenyltetrahydrofuran-2-yliden)amino]propanoate 
(14c). According to GP 7 from 4f (168 mg, 0.5 mmol), 5 ml of MeOH, CC 
(CH2Cl2/acetone 25:1). Yield:  77 mg (56%) of 14c. Colorless oil. 1H-NMR: 1.45, 1.46, 
1.49 (3s, Me, Me2C) ; 2.73-2.79, 2.97-3.02 2 (2m, CH2); 3.68 (s, MeO); 4.31 (s, CH2O); 
7.16-7.36 (m, 5 arom. H). 13C-NMR: 26.1, 26.7, 27.1 (3q, Me, Me2C); 43.0 (t, CH2); 44.6 
(s, Me2C); 51.3 (q, MeO); 60.1 (s, Me2C); 80.9 (t, CH2O); 127.3, 126.8, 128.7 (3d, 5 
arom. CH); 144.5 (s, arom. C); 163.0 (s, C=N); 176.7 (s, C=O). CI-MS: 276 (100, [M + 
H]+), 108 (22). 
8.4. Ethyl 1-[(4,4-Dimethyltetrahydrofuran-2-yliden)amino]cyclopentanecarboxylate 
(14d). According to GP 7 from 4c (135 mg, 0.5 mmol), 5 ml of EtOH, CC 
(CH2Cl2/acetone 20:1). Yield: 71 mg (28%) of 14d and 45 mg (31%) of ethyl 1-(4-
chloro-3,3-dimethylbutanoylamino)cyclopentanecarboxylate (18d) as colorless oils. 
14d: 1H-NMR: 1.12 (s, Me2C); 1.21 (t, J = 7.0, MeCH2); 1.81-1.94 (m, 4 CH2); 2.41 (s, 
CH2); 3.89 (s, CH2O); 4.14 (q, J = 7.0, MeCH2). 13C-NMR: 14.3 (q, Me); 25.1 (q, Me2C); 
37.3, 37.6, 38.4, 39.1 (4t, 4 CH2); 44.2 (s, Me2C); 44.9, 47.1 (2t, 2 CH2); 60.6 (s, Me2C); 
82.2 (t, CH2O); 162.4 (s, C=N); 174.9 (s, C=O). CI-MS: 254 (100, [M + H]+), 200 (18, 
[M - Et]+), 158 (36). 
18d: 1H-NMR: 1.09 (s, Me2C); 1.20 (t, J = 6.9, MeCH2); 1.74-1.82, 1.84-1.94 (2m, 4 
CH2, Me2C); 2.16 (s, CH2); 3.56 (s, CH2O); 4.16 (q, J = 6.9, MeCH2); 6.02 (br. s, NH). 
13C-NMR: 14.2 (q, Me);  24.7, 25.8 (2q, 2 Me2C); 35.8 (s, Me2C); 37.4, 37.7, 38.4, 39.1 
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(4t, 4 CH2); 44.2 (t, CH2); 54.9 (t, CH2O); 61.3 (t, MeCH2); 65.6 (s, Me2C); 170.4, 172.6 
(2s, 2 C=O). CI-MS: 292 (34, [M(37Cl) + H]+), 290 (100, [M(35Cl) + H]+), 254 (28). 
8.5. Methyl 2-(4-Hydroxy-3,3-dimethylbutanoylamino)-2-methylpropanoate (17a). 
According to GP 7 from 9d (174 mg, 0.5 mmol), 5 ml of MeOH, CC (CH2Cl2/acetone 
20:1). Yield: 56 mg (48%) of 17a. Colorless oil. 1H-NMR: 0.98, 1.43 (2s, 2 Me2C); 2.11 
(s, CH2); 3.29 (s, CH2O); 3.78 (s, MeO); 6.25 (s, NH). 13C-NMR: 24.6, 25.2 (2q, 2 
Me2C); 35.7 (s, Me2C); 46.9 (t, CH2); 52.5 (q, MeO); 56.4 (s, Me2C); 71.2 (t, CH2O); 
171.9, 174.9 (2s, 2 C=O). ESI-MS: 254 (100, [M + Na]+). 
8.6. Methyl 2-(4-Hydroxy-3-methyl-3-phenylbutyrylamino)-2-methylpropanoate (17b). 
According to GP G from 9f (205 mg, 0.5 mmol) with 5 ml MeOH, CC (CH2Cl2/acetone 
20:1). Yield 57 mg (38%) of 17b. Colorless oil. 1H-NMR: 1.38 (s, Me2C); 1.39 (s, Me); 
2.47-2.51, 2.66-3.70 (2m, CH2); 3.65-3.69, 3.89-3.92 (2m, CH2O); 3.68 (s, MeO); 6.25 (s,  
NH); 7.19-7.42 (m, 5 arom. H). 13C-NMR: 23.3, 24.5, 24.6 (3q, 3 Me); 43.0 (t, CH2); 46.5 
(s, C); 52.3 (q, MeO); 56.1 (s, C); 70.3 (t, CH2O); 126.0, 126.4, 128.4 (3d, 5 arom. CH); 
145.4 (s, arom. C); 171.2, 174.7 (2s, 2 C=O). CI-MS (i-butane): 294 (100, [M + H]+). 
 
9. Protection of Hydroxy Amide 4d. 9.1. 4-Benzyloxy-3,3-dimethyl-N-[1-methyl-1-(N-
methyl-N-phenylcarbamoyl)ethyl]butanamide (9g). To a soln. of 4d (1 mmol, 306 mg) in  
dry THF (20 ml), NaH (44 mg, 1.1 mmol, 60% suspension in mineral oil) was added at 
0o. After 1 h at r.t., benzylbromide (171 mg, 1 mmol) was added and the mixture heated 
to reflux for 3 h. Washing with brine, extraction with Et2O, drying (MgSO4) and 
evaporation i.v. yielded a colorless oil, which was purified by CC (CH2Cl2/acetone 40:1). 
Yield: 329 mg (73%) of  9g. Colorless oil. 1H-NMR: 0.99, 1.36 (2s, 2 Me2C); 2.18 (s, 
CH2); 3.12 (s, CH2O); 3.22 (s, MeN); 4.43 (s, PhCH2); 5.91 (br. s, NH); 7.12-7.43 (m, 10 
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arom. H). 13C-NMR: 25.4, 26.7 (2q, 2 Me2C); 34.8 (s, Me2C); 41.3 (q, MeN); 46.3 (t, 
CH2); 57.7 (s, Me2C); 73.1 (t, CH2O); 78.5 (t, PhCH2); 127.4, 127.6, 127.7, 127.8, 128.3, 
129.2 (6d, 10 arom. CH); 138.4, 145.0 (2s, 2 arom. C); 170.6, 173.2 (2s, 2 C=O). CI-MS 
(i-butane): 397 (100, [M + H]+). 
9.2. {2,2-Dimethyl-3-[1-methyl-1-(N-methyl-N-phenylcarbamoyl)ethylcarbamoyl]-
propyl}[(9H-fluoren-9-yl)methyl] Carbonate (9h). To a  soln. of 4d (306 mg, 1 mmol) in 
CH2Cl2 (20 ml), pyridine (3 ml) and FmocCl (284 mg, 1.1 mmol) were added. The 
mixture was stirred at r.t. for 3 h, diluted with CH2Cl2 (30 ml), washed with a 10% CuSO4 
soln. and brine, the org. fractions were dried (MgSO4) and evaporated i.v. and purified by 
CC (CH2Cl2/acetone 30:1). Yiled: 450 mg (88%) of 9h. White powder. M.p. 108.9-
110.6o. IR: 3320vs, 2966s, 1745vs, 1678vs, 1650vs, 1599s, 1532s, 1441s, 1386s, 1316m, 
1154m, 964m, 909s, 758m. 1H-NMR: 0.99, 1.39 (2s, 2 Me2C); 1.86 (s, CH2); 3.19 (s, 
MeN); 3.92 (s, CH2O); 1.15 (t, J = 5.8, CH2CH); 4.36 (d, J = 5.8, CH2CH); 6.12 (s, NH); 
7.09-7.32, 7.50-7.80 (2m, 13 arom. H). 13C-NMR: 24.5, 25.5 (2q, 2 Me2C); 34.2 (s, 
Me2C); 41.3 (q, MeN); 45.3 (t, CH2); 58.0 (s, Me2C); 69.7 (t, CH2O); 75.1 (t, CH2CH); 
119.9 (d, CH); 125.0, 127.0, 127.7, 127.8, 127.9, 129.1 (6d, 13 arom. CH); 141.2, 143.3, 
144.5 (3s, 5 arom. C); 155.2 (s, NC(O)O); 169.4, 173.1 (2s, 2 C=O). ESI-MS: 551 (100, 
[M + Na]+). 
9.3. 4-(Benzyloxy)methoxy-3,3-dimethyl-N-[1-methyl-1-(N-methyl-N-phenylcarbamoyl)-
ethyl]butanamide (9i). To a soln. of 4d (306 mg, 1 mmol) in CH2Cl2 (20 ml) was added 
(i-Pr)2NEt (142 mg, 1.1 mmol) and benzyloxymethylchloride (BomCl, 156 mg, 1 mmol). 
The mixture was stirred at r.t. for 12 h, diluted with CH2Cl2 (30 ml), washed with NH4Cl 
soln. and brine, dried (MgSO4), evaporated  i.v. and purified by CC (CH2Cl2/acetone 
40:1). Yield:  375 mg (88%) 9i. Colorless oil. 1H-NMR: 0.99, 1.42 (2s, 2 Me2C); 1.84 (s, 
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CH2); 3.22 (s, MeN); 3.32 (s, CH2); 4.51, 4.68 (2s, CH2); 5.94 (br. s,  NH); 7.08-7.42 (m, 
10 arom. H). 13C-NMR: 25.0, 26.3 (2q, 2 Me2C); 34.5 (s, Me2C); 41.2 (q, MeN); 45.9 (t, 
CH2); 57.8 (s, Me2C); 69.3, 76.2, 94.8 (3t, 3 CH2); 127.6, 127.7, 127.8, 128.3, 129.0, 
129.2 (6d, 10 arom. CH); 137.6, 144.6 (2s, 2 arom. C); 170.2, 173.1 (2s, 2 C=O). CI-MS: 
427 (16, [M + H]+), 320 (100, [M – Ph(Me)N]+), 108 (16). 
 
10. Synthesis of 1,3-Oxazol-5(4H)-ones. 10.1. 3-(4,4-Dimethyl-1,3-oxazol-5(4H)-on-2-
yl)-2,2-dimethylpropyl Acetate  (16a). According to GP 6 from 9d (153 mg, 0.5 mmol), 4 
min HCl gas, CC (CH2Cl2/acetone 40:1). Yield: 123 mg (51%) of 16a. White solid.  M.p. 
99.5-101.7o. Recovered starting material: 33 mg (21%). IR: 3385m, 2976s, 2937s, 
1820vs, 1739vs, 1672vs, 1525m, 1474s, 1379s, 1240vs, 1072s, 1041s, 966s, 897m. 1H-
NMR: 1.05, 1.36 (2s, 2 Me2C); 2.04 (s, MeCO); 2.42 (s, CH2); 3.92 (s, CH2O), 7.21-7.34 
(m, 5 arom. H). 13C-NMR: 20.8 (q, MeCO); 24.4, 24.6 (2q, 2 Me2C); 34.3 (s, Me2C); 38.0 
(t, CH2); 65.3 (s, Me2C); 71.6 (t, CH2O); 161.9 (s, C=N); 170.9, 181.4 (2s, 2 C=O). ESI-
MS: 541 (100, [2(M + H2O) + Na]+), 371  (25), 282 (70, [M + H2O + Na]+). 
10.2. 2-(3-Benzyloxy-2,2-dimethylpropyl)-4,4-dimethyl-1,3-oxazol-5(4H)-one (16b). 
According to GP 6, from 9g (198 mg, 0.5 mmol), 4 min HCl gas, CC (CH2Cl2/acetone 
50:1). Yield:  49 mg (34%) of 16b. White powder. M.p. 104.2-106.0o. Recovered starting 
material: 124 mg (31%). IR: 2951s, 1894s, 2565w,1822vs, 1723vs, 1612vs, 1534vs, 
1458s, 1265s, 1101s, 1058m, 1040m, 911m. 1H-NMR: 1.01, 1.38 (2s, 2 Me2C); 2.48 (s, 
CH2); 3.14 (s, CH2O); 4.56 (s, PhCH2); 7.21-7.34 (m, 5 arom. H). 13C-NMR: 24.5, 24.9 
(2q, 2 Me2C); 35.4 (s, Me2C); 38.3 (t, CH2); 65.2 (s, Me2C); 73.3 (t, CH2O); 78.6 (t, 
PhCH2); 127.5, 128.1, 128.3 (3d, 5 arom. CH); 138.5 (s, arom. C); 162.5 (s, C=N); 182.1 
(s, C=O). CI-MS (i-butane): 290 (18, [M + H]+), 200 (100, [M - Bn]+). 
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10.3. [3-(4,4-Dimethyl-1,3-oxazol-5(4H)-on-2-yl)-2,2-dimethylpropyl][(9H-fluoren-9-
yl)methyl] Carbonate (16c).  According to GP 6 from 9h (169 mg, 0.33 mmol), 4 min 
HCl gas, CC (CH2Cl2/acetone 80:1). Yield: 64 mg (46%) of 16c. White powder. M.p. 
93.8-95.2o. Recovered starting material: 66 mg (39%). IR: 3320s, 2966s, 1821vs, 1745vs, 
1678vs, 1650vs, 1599s, 1532s, 1441s, 1386m, 1316m, 1156m, 909s. 1H-NMR: 1.01, 1.34 
(2s, 2 Me2C); 2.32 (s, CH2); 3.87 (s, CH2O); 4.12 (t, J = 6.0, CH2CH); 4.38 (d, J = 6.0, 
CH2CH); 7.18-7.37, 7.53-7.81 (2m, 8 arom. H). 13C-NMR: 24.3, 24.8 (2q, 2 Me2C); 34.5 
(s, Me2C); 37.9, 46.7 (2t, 2 CH2); 65.1 (s, Me2C); 65.9 (t, CH2O); 69.8 (t, CH2CH); 119.9 
(d, CH);  125.0, 126.8, 127.1, 127.7 (4d, 8 arom. CH); 141.2, 143.3 (2s, 2 arom. C); 
155.0 (s, NC(O)O); 161.6 (s, C=N); 181.1 (s, C=O). CI-MS: 422 (16, [M + H]+), 200 
(100, [M - Fmoc]+), 179 (44). 
10.4. 2-[3-(Benzyloxy)methoxy-2,2-dimethylpropyl]-4,4-dimethyl-1,3-oxazol-5(4H)-one  
(16d). According to GP 6 from 9i (143 mg, 0.33 mmol), 5 min HCl gas, CC 
(CH2Cl2/acetone 60:1). Yield: 42 mg (36%). White solid. M.p. 104.1-105.8o. Recovered 
starting material: 52 mg (35%). 1H-NMR: 0.97, 1.36 (2s, 2 Me2C); 2.42, 3.36, 4.59, 4.73 
(4s, 4 CH2); 7.14-7.43 (m, 5 arom. H). 13C-NMR: 24.4, 24.7 (2q, 2 Me2C); 34.9 (s, 
Me2C); 45.5 (t, CH2); 56.8 (s, Me2C); 69.3, 76.1, 94.8 (3t, 3 CH2); 127.7, 128.3, 129.5 
(3d, 5 arom. CH); 137.6 (s, arom. C); 162.4 (s, C=N); 172.6 (s, C=O). CI-MS (i-butane): 
320 (100, [M + H]+). 
10.5. 2,2-Dimethyl-3-(4-oxo-3-oxa-1-azaspiro[4.4]non-1-en-2-yl)propyl Acetate (16e). 
According to GP 6 from 9c (156 mg, 0.5 mmol), 5 min HCl gas, CC (CH2Cl2/acetone 
30:1). Yield:  45 mg (34%) of 16e. White solid. M.p. 101.1-103.1o. Recovered starting 
material: 33 mg (21%). IR: 3385w, 2976s, 2937s, 1820vs, 1739vs, 1672vs, 1474m, 
1379s, 1240s, 1072s, 1041s, 966m. 1H-NMR: 1.01 (s, Me2C); 1.73-2.04 (m, MeCO, 4 
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CH2); 2.42 (s, CH2); 3.90 (s, CH2O). 13C-NMR: 20.8 (q, MeCO); 24.5 (q, Me2C); 25.8 (t, 
2 CH2); 34.3 (s, Me2C); 38.0, 38.2 (2t, 3 CH2); 71.6 (t, CH2O); 73.9 (s, spiro-C); 161.8 (s, 
C=N); 170.9, 182.1 (2s, 2 C=O). ESI-MS: 593 (100, [2M + H2O + Na]+), 324 (58, [M + 
H2O + K]+), 308 (64, [M + H2O + Na]+), 286 (90, [M + H2O + H]+). 
 
11. 2-[(4,4-Dimethyltetrahydrofuran-2-yliden)amino]-2-methyl-N-[1-methyl-1-(N-
methyl-N-phenylcarbamoyl)ethyl]propanamide (15). To solid 12a (100 mg, 0.42 mmol) a 
soln. of 10b (110 mg, 3 mmol, 1.5 equiv.) in CH2Cl2 (5 ml) was added under vigorous 
stirring. The solvent was immediately removed i.v. and the suspension left at r.t. 
overnight. CC (CH2Cl2/acetone 20:1) yielded  102 mg (64%) of 15. White powder. M.p. 
142.1-143.3o. IR: 3364vs, 2976s, 2937s, 1708vs, 1666vs, 1645vs, 1493s, 1380s, 1223m, 
1111m, 1014s, 781m, 710s. 1H-NMR: 1.08, 1.42, 1.50 (3s, 3 Me2C); 2.26 (s, CH2); 3.21 
(s, MeN); 3.89 (s, CH2O); 7.06-7.29 (m, 5 arom. H); 8.07 (br. s, NH). 13C-NMR: 23.8, 
24.9, 26.1 (3q, 3 Me2C); 36.5 (s, Me2C); 41.0 (q, MeN); 45.2 (t, CH2); 57.3, 60.6 (2q, 2 
Me2C); 81.5 (t, CH2O); 127.3, 128.1, 129.4 (3d, 5 arom. CH); 144.8 (s, arom. C); 161.5 
(s, C=N); 173.6, 176.3 (2s, 2 C=O). ESI-MS: 369 (100, [M + Na]+). 
 
12. Methyl 2-(4-Hydroxy-3,3-dimethyl-2-oxobutylamino)-2-methylpropanoate (19). To a 
soln. of 1-bromo-4-hydroxy-3,3-dimethylbutan-2-one (390 mg, 2 mmol) in Et3N (5 ml),  
methyl 1-amino-2-methylpropanoate hydrochloride (456 mg, 3 mmol) was added. The 
mixture was heated under reflux overnight, cooled, diluted with CH2Cl2 (150 ml) and 
washed with a 10% CuSO4 soln. and brine. Drying (MgSO4), evaporation of the solvent 
and CC (CH2Cl2/acetone 30:1) yielded 195 mg (42%) of 19. Yellow oil. IR: 2973m, 
2884m, 1725vs, 1660vs, 1528m, 1471s, 1364s, 1192s, 1046m. 1H-NMR: 1.12, 1.46 (2s, 2 
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Me2C); 3.50, 3.54 (2s, 2 CH2); 3.71 (s, MeO); 6.74 (br. s, NH). 13C-NMR: 21.1, 25.1 (2q, 
2 Me2C); 48.4 (s, Me2C); 49.9 (t, CH2); 51.9 (q, MeO); 58.2 (s, Me2C); 69.4 (t, CH2O); 
176.4, 212.6 (2s, 2 C=O). CI-MS (i-butane): 232 (70, [M + H]+), 146 (100), 128 (40). 
 
13.  X-ray Crystal-Structure Determination of 11a, 11b, 12g, 12h and 15 (Table and 
Figs. 2-4)6). All measurements were made on a Nonius KappaCCD area-detector 
diffractometer [36] using graphite-monochromated MoKα radiation (λ 0.71073 Å) and an 
Oxford Cryosystems Cryostream 700 cooler. The data collection and refinement 
parameters are given in the Table and views of the molecules are shown in Figs. 2-4. 
Data reduction was performed with HKL Denzo and Scalepack [37]. The intensities were 
corrected for  Lorenz and polarization effects and, in the cases of 11a, 12g  and 12h, an 
absorption correction based on the multi-scan method [38] was applied. Each structure 
was solved by direct methods using SIR92 [39], which revealed the positions of all non-
H atoms. The non-H atoms were refined anisotropically.  
In the case of 11b, there are two independent molecules in the asymmetric unit.  The 
atomic coordinates of the two molecules were tested carefully for a relationship from a 
higher symmetry space group using the program PLATON  [40] but none could be found.  
Each molecule is disordered over two conformations. Two positions were defined for 
each atom of the Cl-(CH2)3- section of each molecule, except for the Cl-substituted C-
atom, which is common to both conformations.  Bond length restraints were applied to all 
bonds involving disordered atoms so as to maintain reasonable geometry. The best results 
                                                  
6)
 CCDC- 286035 - 286040 contain supplementary crystallographic data for this paper. 
These data can be obtained free of charge form the Cambridge Crystallographic Data 
Centre, via http://www.ccdc.cam.ac.uk/data_request/cif 
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were obtained with relative site occupation factors of 0.65:0.35 and 0.80:0.20 for the 
disordered components of molecules A and B, respectively. 
The hydroxy and ammonium H-atoms in 12g and 12h, as well as the amide H-atom in 15 
and the amide and hydroxy H-atoms in 11a and 11b were placed in the positions 
indicated by difference electron density maps and their positions were allowed to refine 
together with individual isotropic displacement parameters. All remaining H-atoms in all 
structures were placed in geometrically calculated positions and each was assigned a 
fixed isotropic displacement parameter with a value equal to 1.2Ueq of its parent atom 
(1.5Ueq for the Me groups). The refinement of each structure was carried out on F2 using 
full-matrix least-squares procedures, which minimized the function Σw(Fo2 – Fc2)2. 
Corrections for secondary extinction were applied, except in the cases of 11a and 11b. 
Neutral atom scattering factors for non-H atoms were taken form [41] and the scattering 
factors for H-atoms were taken from [42]. Anomalous dispersion effects were included in 
Fc [43]; the values for f' and f'' were those of [44]. The values of the mass attenuation 
coefficients are those of [45]. All calculations were performed using the SHELXL97 
program [46]  
 
Table 2. Crystallographic Data of Compounds 11a, 11b, 12g, 12h and 15 
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